Hanyu Pharmaceutical (300199.SZ) issued a profit forecast increase, expecting net profit attributable to shareholders for the first three quarters of RMB 430 million to RMB 450 million, an increase of 502.65%-530.68%.

Zhito Finance APP News, Hybio Pharmaceutical (300199.SZ) released its 2026 first three quarters earnings forecast, expecting net profit attributable to shareholders of the listed company for the first three quarters to be 430 million yuan to 450 million yuan, a year-on-year increase of 502.65%-530.68%. During the reporting period, the net profit attributable to shareholders of the listed company increased significantly year-on-year, mainly due to the continued ramp-up of the company's active pharmaceutical ingredient business during the reporting period, bringing dual growth in revenue and profit. At the same time, the company's R&D investment in projects such as the three-target innovative drug HY3003 and small nucleic acids increased significantly year-on-year.